A detailed history of 1620 Investment Advisors, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 9,291 shares of BMY stock, worth $535,904. This represents 0.39% of its overall portfolio holdings.

Number of Shares
9,291
Previous 10,781 13.82%
Holding current value
$535,904
Previous $447,000 7.38%
% of portfolio
0.39%
Previous 0.37%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$39.66 - $51.75 $59,093 - $77,107
-1,490 Reduced 13.82%
9,291 $480,000
Q2 2024

Jul 23, 2024

SELL
$40.25 - $52.99 $257,318 - $338,765
-6,393 Reduced 37.22%
10,781 $447,000
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $798,675 - $905,542
16,646 Added 3152.65%
17,174 $931,000
Q4 2023

Feb 09, 2024

SELL
$48.48 - $57.85 $460,123 - $549,054
-9,491 Reduced 94.73%
528 $27,000
Q3 2023

Nov 09, 2023

SELL
$57.89 - $64.73 $4,515 - $5,048
-78 Reduced 0.77%
10,019 $581,000
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $12,805 - $14,218
201 Added 2.03%
10,097 $645,000
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $4,599 - $5,217
70 Added 0.71%
9,896 $685,000
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $8,286 - $9,811
121 Added 1.25%
9,826 $706,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $10 - $6,377
83 Added 0.86%
9,705 $690,000
Q2 2022

Aug 09, 2022

BUY
$72.62 - $79.98 $36,092 - $39,750
497 Added 5.45%
9,622 $741,000
Q4 2021

May 16, 2022

BUY
$53.63 - $62.52 $489,373 - $570,495
9,125 New
9,125 $569,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track 1620 Investment Advisors, Inc. Portfolio

Follow 1620 Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 1620 Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on 1620 Investment Advisors, Inc. with notifications on news.